Harrison Miles 4

What Happened

• Harrison Miles, a director of Castle Biosciences (CSTL), was granted 11,766 Restricted Stock Units (RSUs) on May 28, 2026. The reported acquisition price is $0.00 (derivative award), so there was no immediate cash outlay or sale proceeds. Each RSU represents the right to receive one share of common stock upon vesting.

Key Details

• Transaction date: 2026-05-28; Filing date: 2026-06-01 (filing appears to be within the SEC’s two-business-day window).
• Award: 11,766 RSUs; reported price per unit: $0.00 (derivative grant).
• Shares owned after transaction: not specified in the provided filing.
• Footnote highlights: F1 — each RSU equals one share when settled; F2 — RSUs vest in full on the earlier of (a) the one-year anniversary (by May 28, 2027) or (b) the day immediately before the next annual meeting of stockholders.
• Transaction type: Award/Grant (code A). This is compensation-related, not an open-market purchase or sale.

Context

• RSU grants are common director/executive compensation and do not necessarily signal immediate bullish or bearish views by the insider since they vest later and are typically part of pay. Once vested and settled, the shares may be taxable and could be subject to withholding (noted in other filings if applicable).